Introduction
The Docetor 20 mg (Docetaxel) Injection is a microtubule-targeted chemotherapy agent designed to treat advanced and metastatic cancers, including breast, lung, prostate, gastric, and head/neck malignancies. Manufactured by Eskayef Pharmaceuticals Ltd., a leader in oncology innovation, and supplied globally by Onco Solution, a trusted provider of life-saving cancer therapies, the Docetor 20 mg (Docetaxel) Injection disrupts cancer cell division by stabilizing microtubules, effectively halting tumor progression. With its proven efficacy in diverse cancer types and flexible dosing regimens, this injection is a cornerstone of modern oncology, offering hope to patients with aggressive or refractory diseases.
Key Features & Indications
The Docetor 20 mg (Docetaxel) Injection is indicated for:
- Breast Cancer: Single-agent therapy for metastatic cases post-chemotherapy failure, or adjuvant use with doxorubicin and cyclophosphamide.
- Non-Small Cell Lung Cancer (NSCLC): Post-platinum failure monotherapy or combined with cisplatin for untreated advanced NSCLC.
- Prostate Cancer: Combined with prednisone for metastatic castration-resistant prostate cancer (CRPC).
- Gastric Adenocarcinoma & SCCHN: Used with cisplatin/fluorouracil for advanced gastric or head/neck cancers.
Pharmacology
The Docetor 20 mg (Docetaxel) Injection contains docetaxel, which binds to tubulin, promoting dysfunctional microtubule assembly. This disrupts mitosis, leading to cancer cell apoptosis. Unlike other spindle poisons, docetaxel retains activity against multidrug-resistant tumors, making it critical for refractory cases.
Dosage & Administration
- Standard Regimen: Administered intravenously over 1 hour every 3 weeks.
- Breast Cancer: 60–100 mg/m² (metastatic) or 75 mg/m² (adjuvant).
- NSCLC/Prostate/Gastric/SCCHN: 75 mg/m² combined with cisplatin or fluorouracil.
- Premedication: Oral corticosteroids (e.g., dexamethasone) to reduce hypersensitivity risk.
Safety Profile
- Common Side Effects: Neutropenia, anemia, nausea, alopecia, fatigue.
- Severe Risks: Hypersensitivity (anaphylaxis), myelosuppression, ischemic colitis.
- Contraindications: Neutrophil counts <1,500 cells/mm³; hypersensitivity to polysorbate 80.
Why Choose Docetor 20 mg (Docetaxel) Injection?
- Proven Efficacy: Clinically validated for multiple cancer types.
- Quality Assurance: Produced by Eskayef Pharmaceuticals Ltd., a pioneer with 30+ years in oncology.
- Global Reach: Supplied by Onco Solution, ensuring timely access to therapies worldwide.
Conclusion
The Docetor 20 mg (Docetaxel) Injection stands as a vital tool in the fight against advanced cancers, combining targeted microtubule inhibition with adaptable dosing for diverse malignancies. Backed by Eskayef Pharmaceuticals Ltd.’s rigorous quality standards and Onco Solution’s global distribution network, this therapy empowers clinicians to deliver precision care while prioritizing patient safety.
